Holen Sie sich die Stockscreener-App
2.73
1.09%
-0.03
Handel nachbörslich:
2.70
-0.03
-1.10%
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
CATX stock touches 52-week low at $2.6 amid market fluctuations - Investing.com
Vontobel Holding Ltd. Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (CATX) Stock Price, News & Analysis - MarketBeat
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - The Manila Times
Perspective Therapeutics, Inc. to Report Full Year 2024 Financial Results and Business Update on March 26, 2025 - Nasdaq
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - GlobeNewswire Inc.
Perspective Therapeutics (NYSE:CATX) vs. Titan Medical (NASDAQ:TMDIF) Head to Head Analysis - Defense World
SG Americas Securities LLC Has $83,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Examining the Potential Price Growth of Perspective Therapeutics Inc (CATX) - Knox Daily
Cantor Fitzgerald Estimates CATX FY2024 Earnings - MarketBeat
Ratios Uncovered: Breaking Down Perspective Therapeutics Inc (CATX)’s Trailing Twelve Months Metrics - The Dwinnex
Perspective Therapeutics (NYSE:CATX) Upgraded at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Predicts CATX FY2024 Earnings - Defense World
Amicus Therapeutics Inc Inc. (FOLD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
The radiopharma landscape takes shape in neuroendocrine tumors - BioCentury
Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Its Stock Has Paid Off Big Time For Perspective Therapeutics Inc - SETE News
CATX overperforms with a 1.52 increase in share price - US Post News
ForexTV | Small Business Resources - ForexTV.com
Perspective Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Precision Oncology Pioneer Perspective Therapeutics Takes Center Stage at Oppenheimer and B. Riley Conferences - StockTitan
Analysts review Perspective Therapeutics Inc’s rating - Knox Daily
Achilles Therapeutics Plc ADR Inc. (ACHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Analyzing Endeavor Group Holdings Inc (EDR) After Recent Trading Activity - Knox Daily
JPMorgan Chase & Co. Has $333,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
JNM Publishes Guideline for FAP PET - Imaging Technology News
Lucid raises Perspective Therapeutics stock target to $20 By Investing.com - Investing.com Australia
Lucid raises Perspective Therapeutics stock target to $20 - Investing.com India
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from Wedbush - MarketBeat
Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars - AOL
Perspective Therapeutics, Inc. Continues to Pursue Dose Escalation of [212Pb) Vmt-A-Net in Its Ongoing Phase 1/2A Clinical Trial Based on Updated Interim Data Presented At the 2025 Asco Gastrointestinal Cancers Symposium - Marketscreener.com
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium - The Manila Times
Perspective's Cancer Drug Shows Promising Results in Phase 1/2a Trial, Zero Toxicity Issues - StockTitan
Cantor Fitzgerald Forecasts CATX FY2025 Earnings - Defense World
Brokers Offer Predictions for CATX FY2025 Earnings - MarketBeat
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 - The Manila Times
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 - The Manila Times
Nuclear Medicine Market Size & Global Growth Report [2032] - Fortune Business Insights
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Financial Survey: Beyond Air (NASDAQ:XAIR) versus Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Perspective Therapeutics' (CATX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Perspective Therapeutics provides business updates, strategic priorities - Yahoo Finance
Perspective Therapeutics (NYSE:CATX) Receives Outperform Rating from Wedbush - Defense World
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics Advances Cancer Pipeline with $227.8M Cash Runway Through 2026 - StockTitan
Barclays PLC Has $1.52 Million Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Neumora Therapeutics Inc (NMRA): A New Perspective - Stocks Register
Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics CEO to Present at JP Morgan Healthcare Conference and Biotech Showcase - StockTitan
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Jane Street Group LLC - Defense World
1.10%
0.57%
Kapitalisierung:
|
Volumen (24h):